OCTAPHARMA
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1983-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.octapharma.com/
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
- Conditions
- Significant Bleeding RiskVitamin K-Dependent Coagulation Defect
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 3574
- Registration Number
- NCT06429787
- Locations
- 🇺🇸
Octapharma Research Site, Boston, Massachusetts, United States
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 124
- Registration Number
- NCT06361537
- Locations
- 🇺🇦
Octapharma Research Site, Lviv, Ukraine
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
- Conditions
- Acquired Antithrombin Deficiency
- Interventions
- Drug: Human plasma derived antithrombinDrug: Placebo
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 120
- Registration Number
- NCT06096116
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 28
- Registration Number
- NCT05936580
- Locations
- 🇺🇸
UT Health San Antonio, San Antonio, Texas, United States
🇫🇮Helsinki University Hospital,Coagulation Disorder Unit, Helsinki, Finland
🇫🇷Avenue de la République, Chambray-lès-Tours, France
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 28
- Registration Number
- NCT05935358
- Locations
- 🇮🇳
St. John's Medical College Hospital, Bengaluru, India
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
ðŸ‡ðŸ‡·University Hospital Centre Zagreb, Zagreb, Croatia
Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery
- Conditions
- Bleeding Cardiac Surgery Patients
- Interventions
- Drug: Frozen Plasma Product, Human
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 419
- Registration Number
- NCT05523297
- Locations
- 🇺🇸
Duke University Health System, Durham, North Carolina, United States
🇨🇦University of British Columbia and Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada
🇨🇦Sunnybrook Hospital, Toronto, Ontario, Canada
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 12
- Registration Number
- NCT04953884
- Locations
- 🇲🇰
PHI University Clinic for Child Diseases, Skopje, North Macedonia
🇷🇺FSBI National Research Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
🇺🇦Danylo Halytsky Lviv National Medical University, Communal Institution of Lviv Regional Council "Western Ukrainian Specialized Children's Medical Centre", Lviv, Ukraine
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
- Conditions
- Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 30
- Registration Number
- NCT04929236
- Locations
- 🇺🇸
Octapharma Research Site, Charlottesville, Virginia, United States
Efficacy of Atenativ in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 38
- Registration Number
- NCT04918173
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 260
- Registration Number
- NCT04867837
- Locations
- 🇬🇪
Tbilisi Institute of Medicine, Tbilisi, Georgia
🇬🇪LTS ,, Israel-Geoargian Medical Research clinic Helsicore", Tbilisi, Georgia
🇬🇪New Hospitals, Tbilisi, Georgia